Trial Profile

Open-label Dose-finding Trial to Explore Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of BI 3706674 Given Orally as Monotherapy in Patients With Unresectable Metastatic KRAS Wild Type Amplified Gastric, Oesophageal, and Gastroesophagealjunction Adenocarcinoma

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 02 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BI-3706674 (Primary)
Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Solid tumours
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Boehringer Ingelheim

02 Nov 2023 Status changed from not yet recruiting to recruiting.
06 Oct 2023 New trial record
29 Sep 2023 Planned initiation date changed from 25 Oct 2023 to 18 Oct 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com